Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on February 16, 2017, covering events occurring on February 12, 2017. The filing addresses a significant change in the Company's executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
On February 12, 2017, Walt A. Linscott informed the Board of Directors of his resignation as General Counsel and Secretary of the Company. The resignation is effective March 1, 2017. Mr. Linscott has accepted a position as President, Chief Operating Officer, and General Counsel of a start-up biotechnology company.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the departure of a principal officer. The report notes that Gary Wilcox is serving as the Interim Chief Executive Officer.
Key Facts for Investor Verification
- Walt A. Linscott is resigning as General Counsel and Secretary effective March 1, 2017.
- Mr. Linscott is departing to join a start-up biotechnology company in a senior leadership role.
- There is no mention of a successor for the General Counsel or Secretary roles in this filing.
- Financial performance data is not included in this specific report.